Biotech Stocks Up On Ebola News
International Business Times
Published Oct 01, 2014 09:45AM ET
Updated Oct 01, 2014 10:01AM ET
Biotech Stocks Up On Ebola News
By Kathleen Caulderwood - Biotech stocks are up this morning on news of the first reported case of Ebola in the United States.
Yesterday, the Centres for Disease Control and Prevention announced that a patient was being treated at Texas Health Presbyterian Hospital in Dallas. The adult had traveled to West Africa, and developed symptoms after returning to the U.S., which means health workers are currently tracking down every person the patient had contact with.
On Wednesday morning, stocks of Tekmira Pharmaceuticals Corporation NASDAQ:TKMR were up 26.54 percent in premarket trading. The Canadian company has been working with the U.S. Department of Defense to develop its treatment, TKM-Ebola, which was approved for use during the current outbreak.
BioCryst Pharmaceuticals, Inc. NASDAQ:BCRXsaw its stock jump is up 5.32 percent this morning. The company, based in Research Triangle Park, North Carolina, announced in August that its drug, BCX-4430 would soon be studied in non-human primates.
But they’re not the only biotech firms doing well. A handful of other companies are also researching Ebola treatments and vaccines. Though many have yet to reach human trials, their stocks all received a major boost after Monday’s news.
Sarepta Therapeutics Inc. NASDAQ:SRPT shares were up 4.98 percent, NewLink Genetics Corp. (NASDAQ:NLNK,) which is currently developing an Ebola vaccine, saw its stock jump 2.08 percent. Inovio Pharmaceuticals Inc. (NASDAQ:INO) is up 4.37 percent. NanoViricides Inc NYSE:NNVC is up 15 percent.
Get The News You Want
Written By: International Business Times
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.